World's Best Scientists 2026 revealed!
Eugene P. McFadden

Eugene P. McFadden

D-Index & Metrics

Medicine

D-Index
83
Citations
42112
World Ranking
15362
National Ranking
40

Eugene P. McFadden publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Eugene P. McFadden sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 262 publications — 10th percentile

10% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Eugene P. McFadden D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Eugene P. McFadden sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Eugene P. McFadden is a researcher affiliated with Cork University Hospital in Ireland, with a focus on medicine and cardiology. Their work primarily covers cardiology and cardiovascular medicine, surgery, radiology, nuclear medicine and imaging, economics and econometrics, and internal medicine, with a total of 71 publications in medicine.

The scientist's research topics emphasize antiplatelet therapy and cardiovascular diseases, coronary interventions and diagnostics, atrial fibrillation management and outcomes, acute myocardial infarction research, cardiac imaging and diagnostics, venous thromboembolism diagnosis and management, and health systems including economic evaluations and quality of life considerations.

Frequent co-authors collaborating with Eugene P. McFadden include:

  • Dik Heg
  • Marco Valgimigli
  • Anna Franzone
  • Stephan Windecker
  • Sergio Leonardi

Significant venues where this researcher has published multiple works include:

  • Journal of the American College of Cardiology
  • Cardiovascular Revascularization Medicine
  • JAMA Cardiology
  • JACC: Cardiovascular Interventions
  • EuroIntervention

Representative recent papers authored or co-authored by Eugene P. McFadden are:

  • P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials, 2021, BMJ
  • P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events, 2023, Journal of the American College of Cardiology
  • P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions, 2023, Journal of the American College of Cardiology
  • Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention, 2024, JAMA Cardiology
  • De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials, 2024, The Lancet

Best Publications

  • Clinical End Points in Coronary Stent Trials A Case for Standardized Definitions

    Donald E. Cutlip;Stephan Windecker;Roxana Mehran;Ashley Boam

  • 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).

    Marco Valgimigli;Héctor Bueno;Robert A Byrne;Jean-Philippe Collet

  • Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.

    Eugène P McFadden;Eugenio Stabile;Evelyn Regar;Edouard Cheneau

  • Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

    Micheal E. Bertrand;Maarten L. Simoons;Keith A.A. Fox;Lars C. Wallentin

  • High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography.

    Nico R. Mollet;Filippo Cademartiri;Carlos A.G. van Mieghem;Giuseppe Runza

  • Late Angiographic Stent Thrombosis (LAST) Events With Drug-Eluting Stents

    Andrew T.L. Ong;Eugène P. McFadden;Evelyn Regar;Peter P.T. de Jaegere

  • Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial

    Elvin Kedhi;Kaiyum Sheik Joesoef;Eugene McFadden;Jochem Wassing

  • Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.

    M. E. Bertrand;Victor Legrand;J. Boland;E. Fleck

  • Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World” The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry

    Pedro A. Lemos;Patrick W. Serruys;Ron T. van Domburg;Francesco Saia

  • Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study.

    Eric Bonnefoy;Frédéric Lapostolle;Alain Leizorovicz;Gabriel Steg

  • Endothelial Progenitor Cell Capture by Stents Coated With Antibody Against CD34 : The HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry

    Jiro Aoki;Patrick W. Serruys;Heleen van Beusekom;Andrew T.L. Ong

  • Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

    Pascal Vranckx;Marco Valgimigli;Peter Jüni;Christian Hamm

  • Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document

    Hector M. Garcia-Garcia;Eugène P. McFadden;Andrew Farb;Roxana Mehran

  • Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation

    Andrew T.L. Ong;Angela Hoye;Jiro Aoki;Carlos A.G. van Mieghem

  • Multislice spiral computed tomography coronary angiography in patients with stable angina pectoris

    Nico R Mollet;Filippo Cademartiri;Koen Nieman;Francesco Saia

  • Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology

    M. E. Bertrand;M. L. Simoons;K. A. A. Fox;L. C. Wallentin

  • Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation

    Sjoerd H. Hofma;Wim J. van der Giessen;Bas M. van Dalen;Pedro A. Lemos

  • Short- and Long-Term Clinical Outcome After Drug-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease Insights From the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital Registries (RESEARCH and T-SEARCH)

    Marco Valgimigli;Carlos A.G. van Mieghem;Andrew T.L. Ong;Jiro Aoki

  • Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study.

    Pedro A. Lemos;Angela Hoye;Dick Goedhart;Chourmouzios A. Arampatzis

  • Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology*

    Michel E. Bertrand;Maarten L. Simoons;Keith A. A. Fox;Lars C. Wallentin

Frequent Co-Authors

Patrick W. Serruys
Patrick W. Serruys University of Galway
Michel E. Bertrand
Michel E. Bertrand University of Lille
Pim J. de Feyter
Pim J. de Feyter Erasmus University Rotterdam
Pedro A. Lemos
Pedro A. Lemos Universidade de São Paulo
Marco Valgimigli
Marco Valgimigli University of Bern
Ron T. van Domburg
Ron T. van Domburg Erasmus University Rotterdam
Filippo Cademartiri
Filippo Cademartiri Fondazione Monasterio
Stephan Windecker
Stephan Windecker University of Bern
Donald E. Cutlip
Donald E. Cutlip Beth Israel Deaconess Medical Center
Pascal Vranckx
Pascal Vranckx Hasselt University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative routes into the healthcare profession can help diversify your career opportunities beyond the traditional MD degree. Many students are now turning to flexible online programs, which allow you to balance life responsibilities while advancing your education. For example, pursuing a career in medical support is easier with online medical billing and coding with financial aid, making it more affordable to break into the healthcare industry.

Nursing also offers a wide range of roles and academic levels. You can enter the field without high-pressure standardized testing thanks to nursing programs without teas, which help make this rewarding profession more accessible. Those interested in leadership and the business side of healthcare might consider enrolling in an accelerated healthcare administration degree to kickstart their management career.

Current nurses looking to advance can take advantage of rn to np bridge program options, moving on to advanced practice roles with specialized clinical training. These diverse online pathways allow aspiring and practicing healthcare professionals to choose the route that best fits their goals and schedules.

Best Scientists Citing Eugene P. McFadden

Trending Scientists

Recently Published Articles